Skip to main content
. 2018 Jun 27;9:1484. doi: 10.3389/fimmu.2018.01484

Table 1.

Targeted receptors for tailored ags delivery.

Receptor Expression Activity Clinical trials
CLEC9A C-type lectin receptor Human: CD11c+ CD141+ XCR1+ conventional DCs (cDCs)
CD14+ CD16- monocytes
MOUSE: plasmacytoid DCs (pDCs)
XCR1+ CD8α+ lymph node-resident dendritic cells (DCs)		 Major histocompatibility complex (MHC) class I
MHC class II
Ag presentation		 –
DEC-205 Endocytic receptor Human: cDCs, monocytes, B cells
MOUSE: CD8α+ DCs
Dermal/interstitial DCs
Langerhans cells		 MHC class I
MHC class II
Ag presentation		 NCT03358719: recruiting
NCT01834248: completed
NCT02166905: recruiting
NCT01522820: completed
CD40 Transmembrane glycoprotein
Surface receptor		 Human/mouse: cDCs and pDCs, monocytes, B cells, endothelial cells DCs activation NCT03329950: recruitinga
NCT02706353: recruiting
NCT03214250: recruiting
NCT03389802: recruiting
NCT03418480: recruiting
NCT03123783: recruiting

aThere are currently more than 30 clinical trials involving the anti-CD40 antibody. Here, the more recent trials regarding DCs-based vaccination strategies are reported.